Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

• Autor(a) principal: Pereira, S
• Data de Publicação: 2008
• Outros Autores: Caixas, U, Branco, T, Germano, I, Lampreia, F, Papoila, A, Monteiro, E
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.10/672
• topic: Infecção por HIV; Hepatite B; Hepatite C; HIV infections; Hepatitis B; Hepatitis C; Efavirenz

AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS: A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS: No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)). CONCLUSION: It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.